Previous close | 33.00 |
Open | 41.66 |
Bid | 37.20 |
Ask | 45.35 |
Strike | 110.00 |
Expiry date | 2024-06-07 |
Day's range | 39.55 - 41.66 |
Contract range | N/A |
Volume | |
Open interest | 667 |
Moderna said Monday its Covid/flu vaccine topped rivals from GSK and Sanofi, and its own Spikevax shot. But Moderna stock fell.
Moderna (MRNA) completes regulatory filing of its Spikevax 2024-2025 formula, targeting the COVID-19 variant JN.1 to the FDA for the upcoming vaccination season.
(Updated - June 10, 2024 11:28 AM EDT)